The
Regenerative Medicine Partnering Terms and Agreements report provides
comprehensive understanding and unprecedented access to the regenerative
medicine including cell therapy, organ regeneration, stem cells and tissue
regeneration partnering deals and agreements entered into by the worlds leading
healthcare companies.
Description
The
Regenerative Medicine Partnering Terms and Agreements report provides
comprehensive understanding and unprecedented access to the regenerative
medicine including cell therapy, organ regeneration, stem cells and tissue
regeneration partnering deals and agreements entered into by the worlds leading
healthcare companies.
- Trends in regenerative medicine
- Deal terms analysis
- Partnering agreement structure
- Partnering contract documents
- Top deals by value
- Most active dealmakers
- Average deal terms for regenerative medicine and stem cells
The
report provides a detailed understanding and analysis of how and why companies
enter regenerative medicine and stem cells partnering deals. The majority of
deals are development stage whereby the licensee obtains a right or an option
right to license the licensors regenerative medicine and stem cells technology.
These deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
This
report provides details of the latest regenerative medicine and stem cells
agreements including cell therapy agreements announced in the healthcare
sector.
Understanding
the flexibility of a prospective partner’s negotiated deals terms provides
critical insight into the negotiation process in terms of what you can expect
to achieve during the negotiation of terms. Whilst many smaller companies will
be seeking details of the payments clauses, the devil is in the detail in terms
of how payments are triggered – contract documents provide this insight where
press releases and databases do not.
This
report contains a comprehensive listing of all regenerative medicine and stem
cells partnering deals announced since 2009 including financial terms where
available including over 650 links to online deal records as disclosed by the
deal parties. In addition, where available, records include contract documents
as submitted to the Securities Exchange Commission by companies and their
partners.
Contract
documents provide the answers to numerous questions about a prospective partner’s
flexibility on a wide range of important issues, many of which will have a
significant impact on each party’s ability to derive value from the deal.
For example,
analyzing actual company deals and agreements allows assessment of the
following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What are the precise rights granted or optioned?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
The
initial chapters of this report provide an orientation of regenerative medicine
dealmaking and business activities. Chapter 1 provides an introduction to the
report, whilst chapter 2 provides an overview of the trends in regenerative
medicine dealmaking since 2009, including details of average headline, upfront,
milestone and royalty terms.
Chapter
3 provides a review of the leading regenerative medicine deals since 2009.
Deals are listed by headline value, signed by big pharma and most active of all
biopharma companies. Where the deal has an agreement contract published at the
SEC a link provides online access to the contract.
Chapter
4 provides a comprehensive listing of the top 50 big pharma companies that are
active in rgenerative medicine partnering with a brief summary followed by a
comprehensive listing of deals, as well as contract documents available in the
public domain. Where available, each deal title links via Weblink to an online
version of the actual contract document, providing easy access to each contract
document on demand.
Chapter
5 provides a comprehensive listing of the top 50 biotech pharma companies that
are active in rgenerative medicine partnering with a brief summary followed by
a comprehensive listing of deals, as well as contract documents available in
the public domain. Where available, each deal title links via Weblink to an
online version of the actual contract document, providing easy access to each
contract document on demand
Chapter
6 provides a comprehensive and detailed review of regenerative medicine
partnering deals signed and announced since 2009, where a contract document is
available in the public domain. The chapter is organized by company A-Z, deal
type (collaborative R&D, co-promotion, licensing etc) and specific therapy
focus.
Chapter
7 provides a comprehensive and detailed review of all regenerative medicine
partnering deals including cell therapy, organ regeneration, stem cells and
tissue regeneration signed and announced since 2009. Each deal title links via
Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
The
report also includes numerous tables and figures that illustrate the trends and
activities in regenerative medicine partnering and dealmaking since 2009.
In
addition, a comprehensive appendix is provided organized by regenerative
medicine partnering company A-Z, deal type and therapy areas. Each deal title
links via Weblink to an online version of the deal record and where available,
the contract document, providing easy access to each contract document on
demand.
In
conclusion, this report provides everything a prospective dealmaker needs to
know about partnering in the research, development and commercialization of
regenerative medicine technologies and products.
Benefits
Regenerative
Medicine Partnering Terms and Agreements provides the reader with the following
key benefits:
- In-depth understanding of regenerative medicine and stem cells deal trends since 2009
- Includes cell therapy, organ regeneration, stem cells and tissue regeneration deals
- Access to headline, upfront, milestone and royalty data
- Analysis of the structure of regenerative medicine and stem cells agreements with numerous real life case studies
- Comprehensive access to actual regenerative medicine and stem cells contracts entered into by the world’s biopharma companies, together with real world clause examples
- Full listing of regenerative medicine and stem cells deals by company A-Z, deal value, deal type, and therapy focus
- Identify leading regenerative medicine and stem cells deals by value since 2009
- Identify the most active regenerative medicine and stem cells dealmakers since 2009
- Detailed access to actual regenerative medicine and stem cells contracts enter into by the leading fifty big pharma companies
- Insight into the terms included in a regenerative medicine and stem cells agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Spanning
over 1116 pages, “Regenerative Medicine
Partnering Terms and Agreements” report covering the Introduction, Trends
in regenerative medicine dealmaking, Leading regenerative medicine deals, Big
pharma regenerative medicine deals, Big biotech regenerative medicine deals,
Regenerative medicine partnering contracts directory, Regenerative medicine
dealmaking by technology type, Appendices.
Know more about this report
at
– http://mrr.cm/ZDG
To
browse more Pharma and Healthcare Reports visit:
No comments:
Post a Comment
Note: only a member of this blog may post a comment.